August 2026

“Why was I turned down?” is one of the hardest conversations in transplant hepatology — and one of the most misunderstood. Patients often assume a “no” is final. In most cases, it isn’t. It’s a “not yet,” tied to a specific, often reversible reason. Understanding the real categories — permanent vs. temporary, medical vs. donor-related — changes how patients respond to a difficult evaluation outcome. If you’re wondering whether you should be evaluated at all, start with am I a good candidate for a liver transplant. The two categories that matter Absolute contraindications — conditions where transplant surgery itself would very likely do more harm than the disease being treated, regardless of timing. Relative / reversible contraindications — conditions that currently make transplant unsafe or premature, but that can potentially be treated, stabilized, or resolved before reassessment. Most patients I see who are initially declined fall into the second category. That distinction is worth repeating to every patient who hears “no” for the first time. Absolute contraindications Active, uncontrolled extrahepatic malignancy (cancer outside the liver that has spread) Severe, irreversible cardiac or pulmonary disease that makes major surgery unsafe Ongoing, uncontrolled sepsis Advanced HCC with extensive vascular invasion or spread beyond transplant criteria Inability to comply with lifelong immunosuppression (severe, unaddressed psychiatric or cognitive impairment without a support structure) Relative contraindications — the “not yet” category This is where most real-world evaluations land, and where careful management can change the outcome entirely. Active alcohol or substance use. I don’t apply a fixed abstinence period as a hard rule — this is genuinely case-by-case. What I weigh: whether this is a first episode or a recurrent pattern of alcohol-related hepatitis, the strength of the patient’s social and psychological support system, and — critically — insight. A patient who understands why they’re here and what a relapse would cost them post-transplant is a different case from one who doesn’t, even if the liver numbers look identical. Duration of abstinence expected before listing follows the same case-by-case logic, not a fixed calendar rule. Active infection. A controlled, treated infection is not an automatic exclusion — carefully selected cases can proceed once infection is under control, rather than waiting for complete resolution in every instance. Poor nutritional status / sarcopenia. Often addressable with a pre-transplant optimization program rather than disqualifying on its own. Uncontrolled cardiac risk factors. Frequently manageable with cardiology optimization before reassessment. Advanced age alone. Age is just a number. I’ve evaluated physiologically fit patients well beyond the age most people assume is a cutoff — what matters is functional status, not the birth certificate. Psychosocial instability or lack of support system. Often addressable through counseling and building a support plan, not an automatic exclusion. When I see this on evaluation, I don’t treat it as a closed door — I sit down with the patient and family, name the gap plainly, and work out concretely who fills it: a family member taking responsibility for medication timing, a structured follow-up plan, a social worker brought in early. The goal is a real support plan on paper before relisting, not a vague reassurance. Case: recovery without transplant. A young male presented with a first episode of severe alcoholic hepatitis — a Maddrey discriminant function score above 80, meeting criteria for severe disease, and a clinical picture that looked transplant-bound on the surface. A sepsis screen came back negative. With steroid therapy and aggressive nutritional support, he recovered without needing transplantation. This is the case I point to when patients assume a severe presentation automatically means surgery — a first episode, in the right patient, with the right support, can resolve with medical management alone. Donor-side disqualification (LDLT-specific) In living donor transplant, the donor can also be found unsuitable, independent of the recipient’s status: Blood type incompatibility — not automatically disqualifying. ABO-incompatible (ABOI) transplant is an option in selected patient cohorts. In adult living-donor series with modern desensitization protocols (rituximab-based), reported 1-, 3-, and 5-year patient survival runs in the low-to-mid 70s–80s percent range, broadly comparable to ABO-compatible LDLT in the same cohorts — for example, one adult cohort reported 1-/3-/5-year survival of 81.7%/75.7%/71.0% for ABOI versus 81.0%/75.2%/71.5% for ABO-compatible recipients, with 3-year graft and patient survival of 89.2% and 92.3% respectively. Insufficient graft-to-recipient weight ratio Donor medical conditions that make major surgery unsafe for a healthy person Evidence of coercion or lack of true informed consent — donor evaluation includes independent psychological assessment specifically to screen for this Case: ABOI, early transplant in ACLF. A 55-year-old male with acute-on-chronic liver failure was deteriorating rapidly — this was a case where waiting for a matched donor wasn’t a realistic option given the trajectory. His wife came forward to donate. She was not a blood-group match, and the transplant proceeded as an ABO-incompatible transplant, within the selected-cohort protocol where outcomes are acceptable with appropriate desensitization and monitoring. Early transplantation in this setting is often the deciding factor between survival and rapid decline. When a willing donor is found unsuitable, how that’s communicated matters as much as the medical decision itself. My approach: thank them explicitly for their generosity, then be direct — a thorough evaluation has determined we cannot safely proceed, because donor safety is the absolute priority in this field, full stop. I make clear this isn’t a reflection of their health in general — it means their specific anatomy isn’t suited to the extreme demands of donation, which is a narrow, technical finding, not a verdict on them as a person. It’s difficult news, but protecting the donor’s long-term wellbeing is non-negotiable, and we turn immediately to exploring alternative options for the patient rather than leaving the family at a dead end. What happens after a “no” Being declined at one point in time is not a permanent verdict for most relative contraindications. The typical path: Identify the specific reversible factor Treat or optimize it Reassess at an interval matched to the clinical picture Timelines aren’t one-size-fits-all. In the most rapidly progressive